Iovance Biotherapeutics, Inc. - Common Stock (IOVA)

Wall Street may be overestimating these companies' potential.

Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Let's have a look at the gap up and gap down stocks in today's session.

Adaptimmune Therapeutics plc (NASDAQ: ADAP) has sent shockwaves through the biotechnology sector with its announcement on October 20, 2025, of a voluntary delisting of its American Depositary Shares (ADSs) from the Nasdaq Capital Market. The news triggered an immediate and dramatic 62.5% plunge in the company's stock during premarket

October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (NASDAQ: TSTN), the notion of its stock reaching a $100 valuation stands in stark contrast to its current precarious financial and operational state. Despite the transformative

Is there a glimmer of hope for either of these underperforming healthcare companies?

Investors have certainly seen explosive gains from shares of biopharma companies in similar situations.

This biotech company is innovative, but the market demands more than that.

The company hasn't been popular among investors since winning its first FDA approval more than a year ago.

The company announced a flotation of its common shares that is potentially quite dilutive.

Time is running out for the company to mount a comeback.

One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country.

As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth.

The company's top line nearly doubled.